Status:
UNKNOWN
Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy
Lead Sponsor:
Ochsner Health System
Collaborating Sponsors:
Cumberland Pharmaceuticals
Conditions:
Nephropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In patients undergoing coronary angiography, the incidence of contrast induced nephropathy(CIN)varies widely and ranges from \< 5% in the lowest risk patients, to nearly 50% in the highest risk patien...
Eligibility Criteria
Inclusion
- 18 years of age or older.
- Hospitalized with a primary diagnosis of acute coronary syndrome.
- Scheduled for coronary angiography or intervention during the current hospitalization.
Exclusion
- Have end-stage renal disease (ESRD) requiring dialysis.
- Have a known hypersensitivity to NAC.
- Have a history of life-threatening contrast reaction. -
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2010
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00939913
Start Date
January 1 2007
End Date
May 1 2010
Last Update
September 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ochsner Medical Center
New Orleans, Louisiana, United States, 70121